Brief Article
Copyright ©2010 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Sep 14, 2010; 16(34): 4357-4362
Published online Sep 14, 2010. doi: 10.3748/wjg.v16.i34.4357
Standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori eradication
Xiao-Zhong Gao, Xiu-Li Qiao, Wen-Chong Song, Xiao-Feng Wang, Feng Liu
Xiao-Zhong Gao, Xiu-Li Qiao, Wen-Chong Song, Xiao-Feng Wang, Feng Liu, Division of Gastroenterology, Weihai Municipal Hospital, Weihai 264200, Shandong Province, China
Author contributions: Gao XZ, Qiao XL and Song WC contributed equally to this work; Gao XZ designed research; Gao XZ, Qiao XL, Song WC, Liu F and Wang XF performed research; Gao XZ and Liu F provided new reagents/analytic tools; Qiao XL and Song WC analyzed data; Gao XZ, Qiao XL and Song WC wrote the paper.
Correspondence to: Xiao-Zhong Gao, Professor, Division of Gastroenterology, Weihai Municipal Hospital, Weihai 264200, Shandong Province, China. swc1975@hotmail.com
Telephone: +86-631-5287097 Fax: +86-631-5224816
Received: April 3, 2010
Revised: May 11, 2010
Accepted: May 18, 2010
Published online: September 14, 2010
Abstract

AIM: To compare the effectiveness of standard triple, bismuth pectin quadruple and sequential therapies for Helicobacter pylori (H. pylori) eradication in a randomized, double-blinded, comparative clinical trial in China.

METHODS: A total of 215 H. pylori-positive patients were enrolled in the study and randomly allocated into three groups: group A (n = 72) received a 10-d bismuth pectin quadruple therapy (20 mg rabeprazole bid, 1000 mg amoxicillin bid, 100 mg bismuth pectin qid, and 500 mg levofloxacin qd); group B (n = 72) received the sequential therapy (20 mg omeprazole bid, 1000 mg amoxicillin bid, in 5 d, followed by 20 mg omeprazole bid, 500 mg tinidazole bid, 500 mg clarithromycin bid, for another 5 d); group C (n = 71) received a standard 1-wk triple therapy (20 mg omeprazole bid, 1000 mg amoxicillin bid, 500 mg clarithromycin bid). After all these treatments, 20 mg omeprazole bid was administrated for 3 wk. H. pylori status was assessed by histology, 13C-urea breath test and rapid urease test at baseline and 4-6 wk after completion of treatment. Ulcer cicatrization was assessed by gastroscopy. χ2 test (P < 0.05) was used to compare the eradication rates and ulcer cicatrisation rates among the three groups.

RESULTS: The eradication rate was 83.33% (60/72) in group A, 88.89% (64/72) in group B, and 80.56% (58/71) in group C. The ulcer cicatrisation rate was 86.44% (51/59) in group A, 90.16% (55/61) in group B, and 84.91% (45/53) in group C. The sequential therapy yielded a higher eradication rate and ulcer cicatrisation rate than the standard triple and bismuth pectin quadruple therapies. Statistically, the eradication rate of group B was significantly different from groups A and C (P < 0.05), but the difference of ulcer cicatrisation rate and side effects was not statistically significant among the three groups (P > 0.05). The three protocols were generally well tolerated.

CONCLUSION: The sequential therapy has achieved a significantly higher eradication rate, and is a more suitable first-line alternative protocol for anti-H. pylori infection compared with the standard triple and bismuth pectin quadruple therapies.

Keywords: Helicobacter pylori, Sequential therapy, Triple therapy, Bismuth pectin quadruple therapy, Eradication rate